The growth in oligonucleotide therapeutics presents many challenges and opportunities for the manufacture of oligonucleotides, including capacity, scale, sustainability and cost.
Current manufacturing approaches rely on solid support-based synthesis, but the development of a range of alternative technologies offers opportunities to address some of the limitations of solid phase synthesis, but also create some new challenges.
Here, CPI will discuss its collaborative programs (Grand Challenges) and how they look to address these challenges.
Webinar Learning Objectives:
- A better understanding of current and future oligo manufacturing processes
- How sustainability and other challenges are driving development in this area
- A route to form collaborative programs to participate in this and future challenge areas
